Partnering to Bring Meaningful Science to Patients
We are building partnerships that advance science with the urgency that today's global health challenges demand. Our collaborations, including in- and out-licensing, co-promotions, equity investments, divestitures, and M&A, are critical to who we are and how we work.
- Infectious Diseases & Hospital-Based Critical Care Therapies
- Central Nervous System (CNS)
- Rare & Orphan Conditions
ViiV Healthcare
Alongside GlaxoSmithKline (GSK) and Pfizer, we are collaborating with ViiV Healthcare to produce vital medicines for treating and preventing HIV/AIDS. Our collaboration has produced several treatment options over the last decade, including dolutegravir and cabotegravir. Today, Shionogi continues to develop innovative HIV therapies.
Duchesnay
Our collaboration with Duchesnay, a specialty pharma company focusing on women's health, provides for distribution and marketing of Osphena® (ospemifene), a compound developed by Shionogi, in the U.S. and Canada.
BioDelivery Sciences, Inc.
Our collaboration with BioDelivery Sciences Inc., a wholly owned subsidiary of Collegium, was structured as an out-licensing of Symproic® (naldemedine) in the U.S. Shionogi developed Symproic® for patients with opioid-induced constipation.
Roche
In a license and collaboration agreement with the Roche Group, we developed Xofluza® (baloxavir marboxil), an influenza medication, for Roche to commercialize in the U.S.